GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cynosure Inc (NAS:CYNO) » Definitions » Owner Earnings per Share (TTM)

Cynosure (Cynosure) Owner Earnings per Share (TTM) : 0.00 (As of Dec. 2016)


View and export this data going back to 2005. Start your Free Trial

What is Cynosure Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Cynosure's Owner Earnings per Share (TTM) ended in Dec. 2016 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Cynosure's Owner Earnings per Share (TTM) or its related term are showing as below:



CYNO's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 33.41
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Cynosure's Earnings per Share (Diluted) for the three months ended in Dec. 2016 was $0.03. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2016 was $0.59. It's PE Ratio ratio for today is 111.86.

Cynosure's EPS without NRI for the three months ended in Dec. 2016 was $0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2016 was $0.59. It's PE Ratio without NRI ratio for today is 111.86.


Cynosure Owner Earnings per Share (TTM) Historical Data

The historical data trend for Cynosure's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynosure Owner Earnings per Share (TTM) Chart

Cynosure Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 -0.18 1.29 1.07 1.09

Cynosure Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 1.20 1.69 1.35 1.09

Competitive Comparison of Cynosure's Owner Earnings per Share (TTM)

For the Medical Devices subindustry, Cynosure's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cynosure's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cynosure's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Cynosure's Price-to-Owner-Earnings falls into.



Cynosure Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Cynosure's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 14.2
Depreciation, Depletion and Amortization 20.7
Change In Deferred Tax -2.0
5Y Average of Maintenance Capital Expenditure 7.7
Change In Working Capital 0.5
Shares Outstanding (Diluted Average) 23.7

1. Start with "Net Income" from income statement. Cynosure's Net Income for the trailing twelve months (TTM) ended in Dec. 2016 was $14.2 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Cynosure's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2016 was $20.7 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Cynosure's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2016 was $-2.0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $7.7 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Cynosure's 5-Year Average Maintenance Capital Expenditure = $7.7 Mil

5. "Change In Working Capital" is from cashflow statement. Cynosure's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2016 was $0.5 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Cynosure's Shares Outstanding (Diluted Average) for the months ended in Dec. 2016 was 23.706 Mil.

Cynosure's Onwer Earnings Per Share for Dec. 2016 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 14.201 +20.664+-1.965
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-7.6839246481078+0.522)/23.706
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=66.00/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Cynosure Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Cynosure's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cynosure (Cynosure) Business Description

Traded in Other Exchanges
N/A
Address
Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as it expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.
Executives
Thomas H Robinson director C/O CYNOSURE, INC., 5 CARISLE ROAD, WESTFORD MA 01886
Marina Hatsopoulos director 39 MANNING ROAD, BILLERICA MA 01821
George J Vojta director 340 PONDFFIELD ROAD, BROXVILLE NY 10708

Cynosure (Cynosure) Headlines

From GuruFocus

Cynosure: A Value Play on Vanity

By guruek Mike Havrilla 01-19-2009

Small Caps: Assessing Management Guidance and Analysts' Estimates

By Robert Abbott Robert Abbott 11-05-2018

Steven Cohen Invests in Cynosure

By David Goodloe David Goodloe 04-26-2016